Filing Details Aura Biosciences, Inc. (NASDAQ:AURA) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on June 29, 2026. The Healthcare…
Aura Biosciences, Inc. (NASDAQ:AURA) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on June 29, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
Aura Biosciences, Inc.'s stock currently trades at $6.88 with a market capitalization of $413.3M.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing Aura Biosciences, Inc.'s filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for Aura Biosciences, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AURA Stock Page
Browse all filings on our AURA SEC filings page.
Public companies like Aura Biosciences, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
NASDAQ · AURA
Keep reading
